- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Schizophrenia
- Meeting Date: March 2026
Risperidone – March 2026
Subcutaneous injection (modified release) 50 mg in 0.14 mL pre-filled syringe, Subcutaneous injection (modified release) 75 mg in 0.21 mL pre-filled syringe, Subcutaneous injection (modified release) 100 mg in 0.28 mL pre-filled syringe, Subcutaneous injection (modified release) 125 mg in 0.35 mL pre-filled syringe
Public Summary Documents
Last updated
11 March 2026
